Investigational ABC transporter inhibitors

Bibliography

• Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009;109:2989-3011
   PubMed Web of Science ®Google Scholar
• ABC Proteins from Bacteria to Man. Elsevier Science Ltd.: Academic Press; London: 2003
   Google Scholar
• Dean M. The Human ATP-Binding Cassette Transporter Superfamily. National Centre for Biotechnology Information; US: 2002
   Google Scholar
• Riordan JR, Rommens JM, Kerem B, Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73
   PubMed Web of Science ®Google Scholar
• Inagaki N, Gonoi T, Clement JPT, Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995;270:1166-70
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34
   PubMed Web of Science ®Google Scholar
• Gatti L, Cossa G, Beretta GL, Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr Med Chem 2011;18:4237-49
   PubMed Web of Science ®Google Scholar
• The ABC Transporters of Human Physiology and Disease: Genetics and Biochemistry of ATP Binding Cassette Transporters. World Scientific, Singapore; 2011
   Google Scholar
• Rust S, Rosier M, Funke H, Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999;22:352-5
   PubMed Web of Science ®Google Scholar
• Wahrle SE, Jiang H, Parsadanian M, Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 2008;118:671-82
   PubMed Web of Science ®Google Scholar
• Shulenin S, Nogee LM, Annilo T, ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004;350:1296-303
   PubMed Web of Science ®Google Scholar
• Harangi M, Kaminski WE, Fleck M, Homozygosity for the 168His variant of the minor histocompatibility antigen HA-1 is associated with reduced risk of primary Sjogren's syndrome. Eur J Immunol 2005;35:305-17
   PubMed Web of Science ®Google Scholar
• Raggers RJ, Vogels I, van Meer G. Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochem J 2001;357:859-65
   PubMed Web of Science ®Google Scholar
• Schwab M, Schaeffeler E, Marx C, Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124:26-33
   PubMed Web of Science ®Google Scholar
• Strautnieks SS, Bull LN, Knisely AS, A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998;20:233-8
   PubMed Web of Science ®Google Scholar
• Smit JJ, Schinkel AH, Oude Elferink RP, Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451-62
   PubMed Web of Science ®Google Scholar
• Paulusma CC, Bosma PJ, Zaman GJ, Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996;271:1126-8
   PubMed Web of Science ®Google Scholar
• Jardetzky O. Simple allosteric model for membrane pumps. Nature 1966;211:969-70
   PubMed Web of Science ®Google Scholar
• Abele R, Tampe R. The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda) 2004;19:216-24
   PubMed Web of Science ®Google Scholar
• Higgins CF, Linton KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol 2004;11:918-26
   PubMed Web of Science ®Google Scholar
• Chen CJ, Chin JE, Ueda K, Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9
   PubMed Web of Science ®Google Scholar
• Martin C, Berridge G, Higgins CF, Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000;58:624-32
   PubMed Web of Science ®Google Scholar
• Sikic BI. Multidrug resistance and stem cells in acute myeloid leukemia. Clin Cancer Res 2006;12:3231-2
   PubMed Web of Science ®Google Scholar
• Cole SP, Bhardwaj G, Gerlach JH, Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Leier I, Buchholz U, Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996;56:988-94
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Leier I, Buchholz U, ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 1994;54:4833-6
   PubMed Web of Science ®Google Scholar
• Berger W, Setinek U, Hollaus P, Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 2005;131:355-63
   PubMed Web of Science ®Google Scholar
• Mitra P, Oskeritzian CA, Payne SG, Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 2006;103:16394-9
   PubMed Web of Science ®Google Scholar
• Pineiro R, Maffucci T, Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 2011;30:142-52
   PubMed Web of Science ®Google Scholar
• Yamada T, Mori Y, Hayashi R, Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. Cancer Res 2003;63:895-901
   PubMed Web of Science ®Google Scholar
• Konig J, Hartel M, Nies AT, Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer 2005;115:359-67
   PubMed Web of Science ®Google Scholar
• Henderson MJ, Haber M, Porro A, ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 2011;103:1236-51
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70
   PubMed Web of Science ®Google Scholar
• Benderra Z, Faussat AM, Sayada L, Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004;10:7896-902
   PubMed Web of Science ®Google Scholar
• Abbott BL, Colapietro AM, Barnes Y, Low levels of ABCG2 expression in adult AML blast samples. Blood 2002;100:4594-601
   PubMed Web of Science ®Google Scholar
• Chapuy B, Koch R, Radunski U, Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia 2008;22:1576-86
   PubMed Web of Science ®Google Scholar
• Steinbach D, Gillet JP, Sauerbrey A, ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 2006;12:4357-63
   PubMed Web of Science ®Google Scholar
• van Waterschoot RA, Lagas JS, Wagenaar E, Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int J Cancer 2010;127:2959-64
   PubMed Web of Science ®Google Scholar
• Iusuf D, van de Steeg E, Schinkel AH. Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol Sci 2012;33:100-8
   PubMed Web of Science ®Google Scholar
• Darby RA, Callaghan R, McMahon RM. P-glycoprotein inhibition: the past, the present and the future. Curr Drug Metab 2011;12:722-31
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida H, Tsukagoshi S, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72
   PubMed Web of Science ®Google Scholar
• Ozols RF, Cunnion RE, Klecker RW Jr, Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987;5:641-7
   PubMed Web of Science ®Google Scholar
• Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996;32A:1070-81
   PubMed Web of Science ®Google Scholar
• Tiwari AK, Sodani K, Dai CL, Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 2011;12:570-94
   PubMed Web of Science ®Google Scholar
• Boesch D, Gaveriaux C, Jachez B, In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991;51:4226-33
   PubMed Web of Science ®Google Scholar
• Friedenberg WR, Rue M, Blood EA, Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 2006;106:830-8
   PubMed Web of Science ®Google Scholar
• Baer MR, George SL, Dodge RK, Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-32
   PubMed Web of Science ®Google Scholar
• Wandel C, Kim RB, Kajiji S, P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999;59:3944-8
   PubMed Web of Science ®Google Scholar
• Germann UA, Ford PJ, Shlyakhter D, Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 1997;8:141-55
   PubMed Web of Science ®Google Scholar
• Germann UA, Shlyakhter D, Mason VS, Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 1997;8:125-40
   PubMed Web of Science ®Google Scholar
• Seiden MV, Swenerton KD, Matulonis U, A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 2002;86:302-10
   PubMed Web of Science ®Google Scholar
• Gandhi L, Harding MW, Neubauer M, A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 2007;109:924-32
   PubMed Web of Science ®Google Scholar
• Fracasso PM, Goldstein LJ, de Alwis DP, Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 2004;10:7220-8
   PubMed Web of Science ®Google Scholar
• Lancet JE, Baer MR, Duran GE, A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res 2009;33:1055-61
   PubMed Web of Science ®Google Scholar
• Stewart A, Steiner J, Mellows G, Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 2000;6:4186-91
   PubMed Web of Science ®Google Scholar
• Abraham J, Edgerly M, Wilson R, A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res 2009;15:3574-82
   PubMed Web of Science ®Google Scholar
• Shepard RL, Cao J, Starling JJ, Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 2003;103:121-5
   PubMed Web of Science ®Google Scholar
• Dantzig AH, Shepard RL, Law KL, Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 1999;290:854-62
   PubMed Web of Science ®Google Scholar
• Rubin EH, de Alwis DP, Pouliquen I, A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 2002;8:3710-17
   PubMed Web of Science ®Google Scholar
• Sandler A, Gordon M, De Alwis DP, A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 2004;10:3265-72
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Draper D, Chen CC, A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 2011;17:569-80
   PubMed Web of Science ®Google Scholar
• Ruff P, Vorobiof DA, Jordaan JP, A randomized, placebo-controlled, double-blind phase II study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol 2009;64:763-8
   PubMed Web of Science ®Google Scholar
• Lancet JE, Baer MR, Duran GE, A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia. Leuk Res 2009;33:1055-61
   PubMed Web of Science ®Google Scholar
• Gekeler V, Ise W, Sanders KH, The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 1995;208:345-52
   PubMed Web of Science ®Google Scholar
• Turk D, Hall MD, Chu BF, Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res 2009;69:8293-301
   PubMed Web of Science ®Google Scholar
• Duan Z, Choy E, Hornicek FJ. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One 2009;4:7415
   PubMed Web of Science ®Google Scholar
• Haber M, Smith J, Bordow SB, Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006;24:1546-53
   PubMed Web of Science ®Google Scholar
• Burkhart CA, Watt F, Murray J, Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res 2009;69:6573-80
   PubMed Web of Science ®Google Scholar
• Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 2010;5:597-615
   PubMed Web of Science ®Google Scholar
• Yague E, Higgins CF, Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther 2004;11:1170-4
   PubMed Web of Science ®Google Scholar
• Huang H, Wang H, Sinz M, Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 2007;26:258-68
   PubMed Web of Science ®Google Scholar
• Susa M, Iyer AK, Ryu K, Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010;5:e10764
   PubMed Web of Science ®Google Scholar
• Ozvegy-Laczka C, Cserepes J, Elkind NB, Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Update 2005;8:15-26
   PubMed Web of Science ®Google Scholar
• Shi Z, Peng XX, Kim IW, Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007;67:11012-20
   PubMed Web of Science ®Google Scholar
• Dai CL, Tiwari AK, Wu CP, Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905-14
   PubMed Web of Science ®Google Scholar
• Nabekura T. Overcoming multidrug resistance in human cancer cells by natural compounds. Toxins (Basel) 2010;2:1207-24
   PubMed Web of Science ®Google Scholar
• Chearwae W, Anuchapreeda S, Nandigama K, Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from turmeric powder. Biochem Pharmacol 2004;68:2043-52
   PubMed Web of Science ®Google Scholar
• Chen Z, Liu F, Ren Q, Suppression of ABCG2 inhibits cancer cell proliferation. Int J Cancer 2010;126:841-51
   PubMed Web of Science ®Google Scholar
• Gillet JP, Gottesman MM. Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol 2011;12:686-92
   PubMed Web of Science ®Google Scholar
• Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010;10:147-56
   PubMed Web of Science ®Google Scholar
• Reid G, Wielinga P, Zelcer N, The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 2003;100:9244-9
   PubMed Web of Science ®Google Scholar
• Leier I, Jedlitschky G, Buchholz U, The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 1994;269:27807-10
   PubMed Web of Science ®Google Scholar
• Holla VR, Backlund MG, Yang P, Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila) 2008;1:93-9
   PubMed Web of Science ®Google Scholar
• Gatti L, Cossa G, Beretta GL, Novel insights into targeting ATP-binding cassette transporters for antitumor therapy. Curr Med Chem 2011;18:4237-49
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84
   PubMed Web of Science ®Google Scholar
• Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010;86:631-7
   PubMed Web of Science ®Google Scholar
• Ahmed F, Arseni N, Glimm H, Constitutive expression of the ATP-binding cassette transporter ABCG2 enhances the growth potential of early human hematopoietic progenitors. Stem Cells 2008;26:810-18
   PubMed Web of Science ®Google Scholar
• Bleau AM, Hambardzumyan D, Ozawa T, PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009;4:226-35
   PubMed Web of Science ®Google Scholar
• Hall MD, Handley MD, Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 2009;30:546-56
   PubMed Web of Science ®Google Scholar
• Gillet JP, Calcagno AM, Varma S, Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA 2011;108:18708-13
   PubMed Web of Science ®Google Scholar